Don’t miss the latest developments in business and finance.

CureVac CEO eyes coronavirus vaccine approval in third quarter of 2021

Haas told a news conference of foreign journalists that the company aimed to initiate rolling review of its vaccine in the first quarter of 2021

Vaccine
Reuters BERLIN
1 min read Last Updated : Nov 13 2020 | 12:02 AM IST

BERLIN (Reuters) - German biotech company CureVac hopes to receive approval for its experimental COVID-19 vaccine in the third quarter of 2021, Chief Executive Franz-Werner Haas said on Thursday.

Haas told a news conference of foreign journalists that the company aimed to initiate rolling review of its vaccine in the first quarter of 2021.

The exact timing for final approval will depend on how many other shots are given the green light over the next few months, he added.

 

(Reporting by Caroline Copley and Ludwig Burger; Editing by Maria Sheahan)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Nov 13 2020 | 12:00 AM IST

Next Story